Pathophysiology of medication overuse headache - An update

Headache

Volumn 54, Issue 1, 2014, Pages 204-210

  Srikiatkhachorn, Anan ^a   Le Grand, Supang Maneesri ^a   Supornsilpchai, Weera ^a   Storer, Robin James ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

diffuse noxious inhibitory control; endogenous pain control system; medication overuse headache; sensitization; serotonin; trigeminal system

Indexed keywords

CALCITONIN; ENDOCANNABINOID; SEROTONIN; SEROTONIN 2A RECEPTOR;

BRAIN CORTEX; DIFFUSE NOXIOUS INHIBITORY CONTROL; DRUG INDUCED HEADACHE; HUMAN; MIGRAINE AURA; NEUROPHYSIOLOGY; NOCICEPTION; PAIN RECEPTOR; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SPREADING CORTICAL DEPRESSION; TRIGEMINUS GANGLION;

DIFFUSE NOXIOUS INHIBITORY CONTROL; ENDOGENOUS PAIN CONTROL SYSTEM; MEDICATION OVERUSE HEADACHE; SENSITIZATION; SEROTONIN; TRIGEMINAL SYSTEM;

ANALGESICS; CALCITONIN GENE-RELATED PEPTIDE; HEADACHE DISORDERS, SECONDARY; HUMANS; RECEPTOR, SEROTONIN, 5-HT2A; TRIGEMINAL GANGLION;

EID: 84892372106     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12224     Document Type: Review

References (67)

1. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
2. Evers S, Marziniak M,. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010; 9: 391-401.
3. Meskunas CA, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME,. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache. 2006; 46: 766-772.
4. Meng ID, Dodick D, Ossipov MH, Porreca F,. Pathophysiology of medication overuse headache: Insights and hypotheses from preclinical studies. Cephalalgia. 2011; 31: 851-860.
5. De Felice M, Ossipov MH, Porreca F,. Persistent medication-induced neural adaptations, descending facilitation, and medication overuse headache. Curr Opin Neurol. 2011; 24: 193-196.
6. De Felice M, Ossipov MH, Porreca F,. Update on medication-overuse headache. Curr Pain Headache Rep. 2011; 15: 79-83.
7. Lance F, Parkes C, Wilkinson M,. Does analgesic abuse cause headaches de novo? Headache. 1988; 28: 61-62.
8. Wilkinson SM, Becker WJ, Heine JA,. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001; 41: 303-309.
9. Bigal ME, Lipton RB,. Excessive acute migraine medication use and migraine progression. Neurology. 2008; 71: 1821-1828.
10. Lantéri-Minet M, Duru G, Mudge M, Cottrel S,. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review. Cephalalgia. 2011; 31: 837-850.
11. Storer RJ, Akerman S, Goadsby PJ,. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol. 2004; 142: 1171-1181.
12. Burstein R,. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2001; 89: 107-110.
13. Akerman S, Holland PR, Goadsby PJ,. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011; 12: 570-584.
14. Coppola G, Schoenen J,. Cortical excitability in chronic migraine. Curr Pain Headache Rep. 2012; 16: 93-100.
15. Ayzenberg I, Obermann M, Nyhuis P, et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia. 2006; 26: 1106-1114.
16. Perrotta A, Serrao M, Sandrini G, et al. Sensitisation of spinal cord pain processing in medication overuse headache involves supraspinal pain control. Cephalalgia. 2010; 30: 272-284.
17. Coppola G, Currà A, Di Lorenzo C, et al. Abnormal cortical responses to somatosensory stimulation in medication-overuse headache. BMC Neurol. 2010; 10: 126: doi. 10.1186/1471-2377-10-126.
18. 2 laser-evoked potential study. Headache. 2012; 52: 792-807.
19. Currà A, Coppola G, Gorini M, et al. Drug-induced changes in cortical inhibition in medication overuse headache. Cephalalgia. 2011; 31: 1282-1290.
20. Aurora SK, Barrodale P, Chronicle EP, Mulleners WM,. Cortical inhibition is reduced in chronic and episodic migraine and demonstrates a spectrum of illness. Headache. 2005; 45: 546-552.
21. Chen WT, Wang SJ, Fuh JL, et al. Visual cortex excitability and plasticity associated with remission from chronic to episodic migraine. Cephalalgia. 2012; 32: 537-543.
22. Fumal A, Laureys S, Di Clemente L, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain. 2006; 129: 543-550.
23. Grazzi L, Chiapparini L, Ferraro S, et al. Chronic migraine with medication overuse pre-post withdrawal of symptomatic medication: Clinical results and fMRI correlations. Headache. 2010; 50: 998-1004.
24. Ferraro S, Grazzi L, Mandelli ML, et al. Pain processing in medication overuse headache: A functional magnetic resonance imaging (fMRI) study. Pain Med. 2012; 13: 255-262.
25. Riederer F, Marti M, Luechinger R, et al. Grey matter changes associated with medication-overuse headache: Correlations with disease related disability and anxiety. World J Biol Psychiatry. 2012; 13: 517-525.
26. Ferraro S, Grazzi L, Muffatti R, et al. In medication-overuse headache, fMRI shows long-lasting dysfunction in midbrain areas. Headache. 2012; 52: 1520-1534.
27. Welch KM, Nagesh V, Aurora SK, Gelman N,. Periaqueductal gray matter dysfunction in migraine: Cause or the burden of illness? Headache. 2001; 41: 629-637.
28. Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A,. Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studies. Headache. 2007; 47: 996-1003.
29. Mainero C, Boshyan J, Hadjikhani N,. Altered functional magnetic resonance imaging resting-state connectivity in periaqueductal gray networks in migraine. Ann Neurol. 2011; 70: 838-845.
30. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995; 1: 658-660.
31. Srikiatkhachorn A, Anthony M,. Serotonin receptor adaptation in patients with analgesic induced headache. Cephalalgia. 1996; 16: 419-422.
32. Srikiatkhachorn A, Anthony M,. Platelet serotonin in patients with analgesic induced headache. Cephalalgia. 1996; 16: 423-426.
33. 2A serotonin receptor in patients with analgesic-induced transformed migraine. Headache. 1998; 38: 534-539.
34. Ayzenberg I, Obermann M, Leineweber K, et al. Increased activity of serotonin uptake in platelets in medication overuse headache following regular intake of analgesics and triptans. J Headache Pain. 2008; 9: 109-112.
35. Pernía-Andrade AJ, Kato A, Witschi R, et al. Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science. 2009; 325: 760-764.
36. Akerman S, Kaube H, Goadsby PJ,. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther. 2004; 309: 56-63.
37. Akerman S, Holland PR, Cannabinoid GPJ,. CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther. 2007; 320: 64-71.
38. Hoffmann J, Supronsinchai W, Andreou AP, Summ O, Akerman S, Goadsby PJ,. Olvanil acts on transient receptor potential vanilloid channel 1 and cannabinoid receptors to modulate neuronal transmission in the trigeminovascular system. Pain. 2012; 153: 2226-2232.
39. Rossi C, Pini LA, Cupini ML, Calabresi P, Sarchielli P,. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: Relation with serotonin levels. Eur J Clin Pharmacol. 2008; 64: 1-8.
40. Cupini LM, Costa C, Sarchielli P, et al. Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiol Dis. 2008; 30: 186-189.
41. Perrotta A, Arce-Leal N, Tassorelli C, et al. Acute reduction of anandamide-hydrolase (FAAH) activity is coupled with a reduction of nociceptive pathways facilitation in medication-overuse headache subjects after withdrawal treatment. Headache. 2012; 52: 1350-1361.
42. Sarchielli P, Rainero I, Coppola F, et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: Findings from cerebrospinal fluid. Cephalalgia. 2008; 28: 714-722.
43. Vieira DSdS, Naffah-Mazzacoratti MdG, Zukerman E, Senne Soares CA, Cavalheiro EA, Peres MFP,. Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine. Headache. 2007; 47: 842-847.
44. Ma W, Zheng WH, Kar S, Quirion R,. Morphine treatment induced calcitonin gene-related peptide and substance P increases in cultured dorsal root ganglion neurons. Neuroscience. 2000; 99: 529-539.
45. Belanger S, Ma W, Chabot JG, Quirion R,. Expression of calcitonin gene-related peptide, substance P and protein kinase C in cultured dorsal root ganglion neurons following chronic exposure to mu, delta and kappa opiates. Neuroscience. 2002; 115: 441-453.
46. Gardell LR, Wang R, Burgess SE, et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci. 2002; 22: 6747-6755.
47. Mao J, Sung B, Ji RR, Lim G,. Chronic morphine induces downregulation of spinal glutamate transporters: Implications in morphine tolerance and abnormal pain sensitivity. J Neurosci. 2002; 22: 8312-8323.
48. Okada-Ogawa A, Porreca F, Meng ID,. Sustained morphine-induced sensitization and loss of diffuse noxious inhibitory controls in dura-sensitive medullary dorsal horn neurons. J Neurosci. 2009; 29: 15828-15835.
49. Johnson JL, Hutchinson MR, Williams DB, Rolan P,. Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment. Cephalalgia. 2013; 33: 52-64.
50. De Felice M, Porreca F,. Opiate-induced persistent pronociceptive trigeminal neural adaptations: Potential relevance to opiate-induced medication overuse headache. Cephalalgia. 2009; 29: 1277-1284.
51. De Felice M, Ossipov MH, Wang R, et al. Triptan-induced latent sensitization: A possible basis for medication overuse headache. Ann Neurol. 2010; 67: 325-337.
52. Chatchaisak D, Srikiatkhachorn A, Maneesri-le Grand S, Govitrapong P, Chetsawang B,. The role of calcitonin gene-related peptide on the increase in transient receptor potential vanilloid-1 levels in trigeminal ganglion and trigeminal nucleus caudalis activation of rat. J Chem Neuroanat. 2013; 47: 50-56.
53. De Felice M, Ossipov MH, Wang R, et al. Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain. 2010; 133: 2475-2488.
54. Supornsilpchai W, le Grand SM, Srikiatkhachorn A,. Cortical hyperexcitability and mechanism of medication-overuse headache. Cephalalgia. 2010; 30: 1101-1109.
55. 2A receptor in the pathogenesis of medication-overuse headache. Headache. 2010; 50: 185-197.
56. Vibulyaseck S, Bongsebandhu-phubhakdi S, le Grand SM, Srikiatkhachorn A,. Potential risk of dihydroergotamine causing medication-overuse headache: Preclinical evidence. Asian Biomed. 2013 (in press).
57. Srikiatkhachorn A, Tarasub N, Govitrapong P,. Effect of chronic analgesic exposure on the central serotonin system. A possible mechanism of analgesic abuse headache. Headache. 2000; 40: 343-350.
58. Reuter U, Salomone S, Ickenstein GW, Waeber C,. Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia. 2004; 24: 398-407.
59. Dobson CF, Tohyama Y, Diksic M, Hamel E,. Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. Cephalalgia. 2004; 24: 2-11.
60. Supornsilpchai W, Sanguanrangsirikul S, Maneesri S, Srikiatkhachorn A,. Serotonin depletion, cortical spreading depression and trigeminal nociception. Headache. 2006; 46: 34-39.
61. le Grand SM, Supornsilpchai W, Saengjaroentham C, Srikiatkhachorn A,. Serotonin depletion leads to cortical hyperexcitability and trigeminal nociceptive facilitation via the nitric oxide pathway. Headache. 2011; 51: 1152-1160.
62. 2A receptor activation and nitric oxide synthesis: A possible mechanism determining migraine attacks. Headache. 2002; 42: 566-574.
63. Maneepak M, le Grand S, Srikiatkhachorn A,. Serotonin depletion increases nociception-evoked trigeminal NMDA receptor phosphorylation. Headache. 2009; 49: 375-382.
64. Le Grand S, Saengjaroentham C, Supronsilpchai W, Srikiatkhachorn A,. The increase in the calcitonin gene-related peptide immunoreactivity following the CSD activation in the serotonin depleted state. J Headache Pain. 2010; 11 (Suppl. 1): S136-S137.
65. Saengjaroentham C, Supornsilpchai W, Srikiatkhachorn A, le Grand SM,. The effect of the serotonin depletion on the cortical spreading depression induced the release of calcitonin gene related peptide (CGRP) and the ultrastructural alteration of the cerebral microvessels. J Neurochem. 2012; 115 (Suppl. 1): 67-67.
66. Allison C, Pratt JA,. Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol Ther. 2003; 98: 171-195.
67. Srikiatkhachorn A,. Chronic daily headache: A scientist's perspective. Headache. 2002; 42: 532-537.